Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR-T Therapy Axicabtagene Ciloleucel – PR Newswire (press release)
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR–T Therapy Axicabtagene Ciloleucel
PR Newswire (press release) Jerrell Shelton, CEO of Cryoport, stated, “Kite’s CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients’ own immune cells to treat cancers. It offers hope to patients who previously had no other option left … |
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR–T Therapy Axicabtagene Ciloleucel
Markets Insider Jerrell Shelton, CEO of Cryoport, stated, “Kite’s CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients’ own immune cells to treat cancers. It offers hope to patients who previously had no other option left … Gilead Sciences Couldn’t Have Timed its Splash Into CAR–T BetterMotley Fool |
Madison.com |
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Madison.com The Kite Pharma deal comes ahead of an expected FDA decision on its CAR–T, axi-cel, on Nov. 29. It’s not a given that axi-cel will get a green light, but it delivered a better than 50% complete response rate in trials, and the FDA opted against holding … |
Xconomy |
Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR–T
Xconomy The FDA has forced Cellectis to shut down two Phase 1 trials it has been running to test an “off the shelf” type of cell therapy—a stinging setback to the France- and New York-based company’s aspirations to leapfrog other developers of CAR–T, a type … FDA hits Cellectis’ off-the-shelf CAR–T program with clinical hold after first patient treated in phase 1 trial diesFierceBiotech In staggering setback, toxic reaction kills Cellectis’ first CAR–T patient, forcing trial haltEndpoints News Cellectis Reports Clinical Hold of UCART123 StudiesBusiness Wire (press release) Reuters –pharmaphorum all 13 news articles » |
FierceBiotech |
FDA hits Cellectis’ off-the-shelf CAR–T program with clinical hold after first patient treated in phase 1 trial dies
FierceBiotech Doctors at the MD Anderson Cancer Center dosed the first blastic plasmacytoid dendritic cell neoplasm (BPDCN) patient with CD123-targeting CAR–T UCART123 on August 16. The patient died nine days later. Initially, the 78-year-old man responded to the … Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR–TXconomy After Patient Death, FDA Places Clinical Hold on Cellectis CAR–T Candidate UCART123Genetic Engineering & Biotechnology News Cellectis Reports Clinical Hold of UCART123 StudiesBusiness Wire (press release) Endpoints News –Reuters –PharmaTimes all 15 news articles » |
|
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Motley Fool … with a historically poor prognosis, too. Together, these developments show chimeric antigen receptor T–cell therapy, or CAR-T, which involves reengineering a patient’s T–cells to spot and destroy cancer cells, could be the next big thing in cancer … |